STOCK TITAN

[8-K] Zoetis Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Zoetis (ZTS) appointed Stephanie Tilenius to its Board of Directors, effective December 1, 2025. The Board will increase from 12 to 13 members on that date.

The company states the appointment was not made pursuant to any third‑party arrangement and notes no related party transactions with Ms. Tilenius since the beginning of the last fiscal year. She will be eligible under Zoetis’ non‑employee director compensation program outlined in its 2025 proxy. Zoetis will enter into its standard indemnification agreement with her, and a press release announcing the appointment was issued on October 28, 2025.

Zoetis (ZTS) ha nominato Stephanie Tilenius al Consiglio di Amministrazione, con effetto dal 1 dicembre 2025. Il Consiglio passerà da 12 a 13 membri in quella data.

La società dichiara che la nomina non è stata effettuata ai sensi di alcun accordo con terzi e osserva che non esistono operazioni con parti correlate con la signora Tilenius dall'inizio dell'ultimo esercizio sociale. Sarà idonea al programma di compensazione per i membri non dipendenti del consiglio di Zoetis, descritto nel suo proxy del 2025. Zoetis stipulerà con lei il suo accordo standard di indennità, e un comunicato stampa annunciante la nomina è stato emesso il 28 ottobre 2025.

Zoetis (ZTS) nombró a Stephanie Tilenius a su Junta Directiva, con efecto a partir del 1 de diciembre de 2025. El Consejo aumentará de 12 a 13 miembros en esa fecha.

La empresa afirma que el nombramiento no se realizó conforme a ningún acuerdo con terceros y señala que no hay transacciones con partes relacionadas con la Sra. Tilenius desde el inicio del último año fiscal. Ella será elegible bajo el programa de compensación para directores no ejecutivos de Zoetis, descrito en su proxy de 2025. Zoetis celebrará su acuerdo estándar de indemnización con ella, y se emitió un comunicado de prensa anunciando el nombramiento el 28 de octubre de 2025.

Zoetis (ZTS)는 2025년 12월 1일부로 이사회에 Stephanie Tilenius를 임명했습니다. 그 날짜에 이사회는 12명에서 13명으로 증가합니다.

회사는 이번 임명이 제3자 계약에 따른 것이 아니며, Tilenius 씨와 관련 당사자 거래가 지난해 말 기준으로 시작된 이후로 없다고 밝힙니다. 그녀는 Zoetis의 비상근 이사 보수 프로그램의 적용 대상이 될 것이며, 이는 2025년 의결권 자료(proxy)에 요약되어 있습니다. Zoetis는 그녀와 표준 면책 계약을 체결할 것이며, 임명 발표는 2025년 10월 28일에 발표문이 발행되었습니다.

Zoetis (ZTS) a nommé Stephanie Tilenius au conseil d'administration, à compter du 1er décembre 2025. Le conseil passera de 12 à 13 membres à cette date.

La société affirme que la nomination n'a pas été réalisée dans le cadre d'un accord avec des tiers et note qu'il n'existe aucune transaction avec des parties liées avec Mme Tilenius depuis le début du dernier exercice fiscal. Elle sera éligible au programme de rémunération des administrateurs non salariés de Zoetis, décrit dans son proxy de 2025. Zoetis conclura avec elle son accord d'indemnisation standard, et un communiqué de presse annonçant la nomination a été publié le 28 octobre 2025.

Zoetis (ZTS) hat Stephanie Tilenius zum Vorstand ernannt, mit Wirkung zum 1. Dezember 2025. Der Vorstand wird an diesem Datum von 12 auf 13 Mitglieder erweitert.

Das Unternehmen erklärt, dass die Ernennung nicht auf einer Drittvereinbarung beruht und stellt fest, dass es seit Beginn des letzten Geschäftsjahres keine Transaktionen mit nahestehenden Personen bezüglich Frau Tilenius gegeben hat. Sie wird gemäß dem Vergütungsprogramm für externe Vorstandsmitglieder von Zoetis in den Proxy 2025 aufgenommen. Zoetis wird mit ihr eine standardmäßige Entschädigungsvereinbarung abschließen, und eine Pressemitteilung über die Ernennung wurde am 28. Oktober 2025 veröffentlicht.

Zoetis (ZTS) عيّنت Stephanie Tilenius في مجلس إدارتها، اعتباراً من 1 ديسمبر 2025. سيزداد عدد أعضاء المجلس من 12 إلى 13 عضواً في ذلك التاريخ.

تذكر الشركة أن التعيين لم يتم بموجب أي ترتيب مع طرف ثالث وتلاحظ عدم وجود معاملات مع طرف ذي علاقة مع السيدة Tilenius منذ بداية آخر سنة مالية. ستكون مؤهلة ضمن برنامج تعويضات مدير غير موظف لدى Zoetis كما هو موضح في تفويضها لعام 2025. ستدخل Zoetis في اتفاقية تعويض قياسية معها، وتم إصدار بيان صحفي يعلن عن التعيين في 28 أكتوبر 2025.

Positive
  • None.
Negative
  • None.

Zoetis (ZTS) ha nominato Stephanie Tilenius al Consiglio di Amministrazione, con effetto dal 1 dicembre 2025. Il Consiglio passerà da 12 a 13 membri in quella data.

La società dichiara che la nomina non è stata effettuata ai sensi di alcun accordo con terzi e osserva che non esistono operazioni con parti correlate con la signora Tilenius dall'inizio dell'ultimo esercizio sociale. Sarà idonea al programma di compensazione per i membri non dipendenti del consiglio di Zoetis, descritto nel suo proxy del 2025. Zoetis stipulerà con lei il suo accordo standard di indennità, e un comunicato stampa annunciante la nomina è stato emesso il 28 ottobre 2025.

Zoetis (ZTS) nombró a Stephanie Tilenius a su Junta Directiva, con efecto a partir del 1 de diciembre de 2025. El Consejo aumentará de 12 a 13 miembros en esa fecha.

La empresa afirma que el nombramiento no se realizó conforme a ningún acuerdo con terceros y señala que no hay transacciones con partes relacionadas con la Sra. Tilenius desde el inicio del último año fiscal. Ella será elegible bajo el programa de compensación para directores no ejecutivos de Zoetis, descrito en su proxy de 2025. Zoetis celebrará su acuerdo estándar de indemnización con ella, y se emitió un comunicado de prensa anunciando el nombramiento el 28 de octubre de 2025.

Zoetis (ZTS)는 2025년 12월 1일부로 이사회에 Stephanie Tilenius를 임명했습니다. 그 날짜에 이사회는 12명에서 13명으로 증가합니다.

회사는 이번 임명이 제3자 계약에 따른 것이 아니며, Tilenius 씨와 관련 당사자 거래가 지난해 말 기준으로 시작된 이후로 없다고 밝힙니다. 그녀는 Zoetis의 비상근 이사 보수 프로그램의 적용 대상이 될 것이며, 이는 2025년 의결권 자료(proxy)에 요약되어 있습니다. Zoetis는 그녀와 표준 면책 계약을 체결할 것이며, 임명 발표는 2025년 10월 28일에 발표문이 발행되었습니다.

Zoetis (ZTS) a nommé Stephanie Tilenius au conseil d'administration, à compter du 1er décembre 2025. Le conseil passera de 12 à 13 membres à cette date.

La société affirme que la nomination n'a pas été réalisée dans le cadre d'un accord avec des tiers et note qu'il n'existe aucune transaction avec des parties liées avec Mme Tilenius depuis le début du dernier exercice fiscal. Elle sera éligible au programme de rémunération des administrateurs non salariés de Zoetis, décrit dans son proxy de 2025. Zoetis conclura avec elle son accord d'indemnisation standard, et un communiqué de presse annonçant la nomination a été publié le 28 octobre 2025.

Zoetis (ZTS) hat Stephanie Tilenius zum Vorstand ernannt, mit Wirkung zum 1. Dezember 2025. Der Vorstand wird an diesem Datum von 12 auf 13 Mitglieder erweitert.

Das Unternehmen erklärt, dass die Ernennung nicht auf einer Drittvereinbarung beruht und stellt fest, dass es seit Beginn des letzten Geschäftsjahres keine Transaktionen mit nahestehenden Personen bezüglich Frau Tilenius gegeben hat. Sie wird gemäß dem Vergütungsprogramm für externe Vorstandsmitglieder von Zoetis in den Proxy 2025 aufgenommen. Zoetis wird mit ihr eine standardmäßige Entschädigungsvereinbarung abschließen, und eine Pressemitteilung über die Ernennung wurde am 28. Oktober 2025 veröffentlicht.

Zoetis (ZTS) عيّنت Stephanie Tilenius في مجلس إدارتها، اعتباراً من 1 ديسمبر 2025. سيزداد عدد أعضاء المجلس من 12 إلى 13 عضواً في ذلك التاريخ.

تذكر الشركة أن التعيين لم يتم بموجب أي ترتيب مع طرف ثالث وتلاحظ عدم وجود معاملات مع طرف ذي علاقة مع السيدة Tilenius منذ بداية آخر سنة مالية. ستكون مؤهلة ضمن برنامج تعويضات مدير غير موظف لدى Zoetis كما هو موضح في تفويضها لعام 2025. ستدخل Zoetis في اتفاقية تعويض قياسية معها، وتم إصدار بيان صحفي يعلن عن التعيين في 28 أكتوبر 2025.

Zoetis (ZTS) 任命 Stephanie Tilenius 为其董事会成员,生效日期为 2025 年 12 月 1 日。届时董事会成员将由 12 名增至 13 名。

公司表示此次任命并非依据任何第三方安排,并指出自上一个财政年度开始以来,Tilenius 女士与公司不存在相关方交易。她将符合 Zoetis 的非雇员董事薪酬计划,该计划在 2025 年代理人书中有所概述。Zoetis 将与她签署其标准的赔偿协议,关于任命的新闻稿已于 2025 年 10 月 28 日发布。

0001555280false00015552802025-10-232025-10-23

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
FORM8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): October 23, 2025
Zoetis Inc.
(Exact name of registrant as specified in its charter)
Delaware001-3579746-0696167
(State or other jurisdiction(Commission File(I.R.S. Employer
of incorporation)Number)Identification No.)
10 Sylvan Way
Parsippany
New Jersey
07054
(Address of principal executive offices)(Zip Code)

(973) 822-7000
(Registrant's telephone number, including area code)
Not Applicable
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareZTSNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

                                     Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 23, 2025, the Board of Directors (the "Board") of Zoetis Inc. (the “Company”) appointed Stephanie Tilenius to the Board, effective as of December 1, 2025, to serve in such capacity until her successor is appointed or qualified or until her resignation or removal. In connection with the appointment of Ms. Tilenius, the size of the Board will be increased from twelve to thirteen members effective as of December 1, 2025.

Ms. Tilenius was not appointed to the Board pursuant to any arrangements or understandings with any third party, and since the beginning of the last fiscal year, there have been no related party transactions between the Company and Ms. Tilenius that would be reportable under Item 404(a) of Regulation S-K. The Company’s non-employee director compensation program is described under the caption “Compensation of Directors” in the Company’s proxy statement for its 2025 Annual Meeting of Shareholders filed with the Securities and Exchange Commission on April 9, 2025. Ms. Tilenius will be eligible for participation in such non-employee director compensation program.

In connection with her appointment as a member of the Board, the Company will enter into its standard form of indemnification agreement with Ms. Tilenius. The form of indemnification agreement was previously filed by the Company as Exhibit 10.19 to Amendment No. 4 to the Company’s Registration Statement on Form S-1 (File No. 333-183254), as originally filed with the Securities and Exchange Commission on August 13, 2012, and subsequently amended.

Item 7.01. Regulation FD Disclosure.

On October 28, 2025, the Company issued a press release announcing the appointment of Ms. Tilenius. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01.

The information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.
(d)    Exhibits
Exhibit No.Description
99.1
Press Release issued on October 28, 2025 regarding the appointment of Stephanie Tilenius
   to the Zoetis Board
104Cover Page Interactive Data File (embedded within the Inline XBRL document)




SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ZOETIS INC.
Dated: October 28, 2025By:/s/ Roxanne Lagano
Roxanne Lagano
Executive Vice President,
General Counsel and Corporate Secretary


FAQ

What did Zoetis (ZTS) announce in this update?

Zoetis appointed Stephanie Tilenius to its Board of Directors, effective December 1, 2025.

How does the Zoetis (ZTS) Board size change?

The Board will increase from 12 to 13 members effective December 1, 2025.

Were there any related party transactions with Stephanie Tilenius?

Zoetis states there have been no related party transactions with Ms. Tilenius since the beginning of the last fiscal year.

Will Stephanie Tilenius receive director compensation at Zoetis (ZTS)?

She will be eligible under Zoetis’ non‑employee director compensation program described in its 2025 proxy.

Is there an indemnification agreement for the new director at Zoetis (ZTS)?

Zoetis will enter into its standard indemnification agreement with Ms. Tilenius.

Did Zoetis (ZTS) issue a press release about the appointment?

Yes. A press release was issued on October 28, 2025 and attached as Exhibit 99.1.
Zoetis Inc

NYSE:ZTS

ZTS Rankings

ZTS Latest News

ZTS Latest SEC Filings

ZTS Stock Data

65.38B
442.76M
0.09%
98.66%
1.75%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
PARSIPPANY